These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21507195)

  • 1. Statin use is associated with lower inflammation and erythropoietin responsiveness index in hemodialysis patients.
    Koc M; Dogan C; Arinsoy T; Tonbul Z; Ayli D; Cirit M; Sever MS; Yilmaz ME; Unsal A; Suleymanlar G; Ok E; Basci A; Yildiz A
    Hemodial Int; 2011 Jul; 15(3):366-73. PubMed ID: 21507195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects.
    Chiang CK; Yang SY; Peng YS; Hsu SP; Pai MF; Huang JW; Hung KY; Wu KD
    Am J Nephrol; 2009; 29(5):392-7. PubMed ID: 18974640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy.
    Sirken G; Kung SC; Raja R
    ASAIO J; 2003; 49(4):422-5. PubMed ID: 12918584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study.
    Li XY; Chang JP; Su ZW; Li JH; Peng BS; Zhu SL; Cai AJ; Zhang J; Jiang Y
    Ther Apher Dial; 2010 Jun; 14(3):308-14. PubMed ID: 20609184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statin treatment and diabetes affect myeloperoxidase activity in maintenance hemodialysis patients.
    Stenvinkel P; Rodríguez-Ayala E; Massy ZA; Qureshi AR; Barany P; Fellström B; Heimburger O; Lindholm B; Alvestrand A
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):281-7. PubMed ID: 17699218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival.
    Snaedal S; Heimbürger O; Qureshi AR; Danielsson A; Wikström B; Fellström B; Fehrman-Ekholm I; Carrero JJ; Alvestrand A; Stenvinkel P; Bárány P
    Am J Kidney Dis; 2009 Jun; 53(6):1024-33. PubMed ID: 19394732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
    Nakamoto H; Mimura T; Honda N
    Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins.
    Hasegawa T; Zhao J; Fuller DS; Bieber B; Zee J; Morgenstern H; Hanafusa N; Nangaku M
    Am J Nephrol; 2017; 46(1):11-17. PubMed ID: 28564644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A vitamin E-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial.
    Panichi V; Rosati A; Paoletti S; Ferrandello P; Migliori M; Beati S; Bernabini G; Daini R; Casani A; Angelini D; Parrini M; Rossi A; Petrone I; Barsotti G; Donadio C; Donati G; Grazi G; Manca Rizza G; Garosi G; Sansoni E; Braccagni B; Sidoti A; Boracelli D; Biagioli M; Moriconi L; Finato V; Mannarino A; Grimaldi C; Pansa F; Imperiali P; Mura C; Bianchi S; Bigazzi R
    Blood Purif; 2011; 32(1):7-14. PubMed ID: 21242686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of high-flux hemodialysis on renal anemia.
    Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
    J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients.
    Bradbury BD; Critchlow CW; Weir MR; Stewart R; Krishnan M; Hakim RH
    Nephrol Dial Transplant; 2009 Mar; 24(3):919-25. PubMed ID: 18840893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
    Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of statins on erythropoietin responsiveness in type 2-diabetic versus non-diabetic hemodialysis patients.
    Tangdhanakanond K; Raja R
    Clin Nephrol; 2010 Jan; 73(1):1-6. PubMed ID: 20040345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins are associated with a reduced risk of bone fracture in hemodialysis (HD) patients.
    Nichols R; Hopman WM; Morton AR; Harman GJ; Holden RM
    Hemodial Int; 2008 Apr; 12(2):275-9. PubMed ID: 18394063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between residual renal function, inflammation, and anemia in peritoneal dialysis.
    Pérez-Flores I; Coronel F; Cigarrán S; Herrero JA; Calvo N
    Adv Perit Dial; 2007; 23():140-3. PubMed ID: 17886621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy.
    Corrao G; Conti V; Merlino L; Catapano AL; Mancia G
    Clin Ther; 2010 Feb; 32(2):300-10. PubMed ID: 20206788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.